BioSpace News Archive

Cytrellis Biosystems , today announced members of the Cytrellis leadership team will participate at the following conferences and events this September.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced the expansion of its patent portfolio following the issuance of a Canadian patent for its Histone Deacetylase (HDAC) inhibitor platform technology titled “Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated (ATM) Activation and Methods of Use Thereof.”

Stealth BioTherapeutics Inc. today announced its achievement of target enrollment in the NuPOWER (SPIMD-301) study in patients with primary mitochondrial myopathy (PMM).

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam.

Therapeutic Solutions International, Inc. (TSOI), announced today the development of a new therapeutic approach for treatment of Frontotemporal Dementia, by combining the activation of endogenous anti-inflammatory cells in the nervous system.

Ocuphire Pharma, Inc. announced that company management will be participating in one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City on September 11-13, 2023.

Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an abstract featuring ELU001, its lead C’Dot Drug Conjugate (CDC) clinical candidate, has been accepted for poster presentation at the ESMO Congress 2023 being held in Madrid, Spain from October 20-24, 2023.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Eric Bjerkholt as chief financial officer (CFO).

Eikon Therapeutics, Inc. announced today that it has completed the previously announced integration of TLR 7 and 8 co-agonists into its clinical development program, and that it expects to discuss the further development of these molecules with the U.S. Food and Drug Administration (FDA) in the fourth quarter.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023.